Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERCEPT Plasma for Acute Ebola Virus Disease
NCT02295501Phase 1Terminated
- Sponsor
- Cerus Corporation
- Start
- Dec 2014
- Primary completion
- Dec 2020
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INTERCEPT Plasma in Ebola virus disease (EVD), sponsored by Cerus Corporation. Primary endpoints: Proportion of subjects who survive EVD at 1 year, Proportion of subjects with adverse events at 24 hours and 1 more. Started Dec 2014; status: terminated.
02
Drugs
INTERCEPT Plasma
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02295501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02295501.